Complement Factor D (Factor D)

Subscribe to Selected New Research on Complement Factor D

86 relevant articles (1 outcomes, 9 trials/studies) found for this Bio-Agent

Description: A serum protein which is important in the ALTERNATIVE COMPLEMENT ACTIVATION PATHWAY. This enzyme cleaves the COMPLEMENT C3B-bound COMPLEMENT FACTOR B to form C3bBb which is ALTERNATIVE PATHWAY C3 CONVERTASE.

Also Known As:

Factor D; Factor D, Complement; 28 kDa Protein, Adipocyte; C3 Proactivator Convertase; C3PAse; Complement Protein D; D Component of Complement; GBGase; Proactivator Convertase; Activator, C3 Convertase; Complement D Component; Convertase Activator, C3; Convertase, C3 Proactivator; Convertase, C3PA; Convertase, Proactivator; Factor D, Properdin; Protein D, Complement; Adipsin; C3 Convertase Activator; C3PA Convertase; Properdin Factor D

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Abrera-Abeleda, M A: 1 article (06/2007)
2.	Sethi, S: 1 article (06/2007)
3.	Xu, Y: 1 article (06/2007)
4.	Pickering, M C: 1 article (06/2007)
5.	Smith, R J H: 1 article (06/2007)
6.	Beck, Hans Peter: 1 article (04/2007)
7.	Wahlgren, Mats: 1 article (04/2007)
8.	Nikolic, Milica: 1 article (04/2007)
9.	Lutz, Hans U: 1 article (04/2007)
10.	Luginbühl, Alexander: 1 article (04/2007)

Related Diseases

1.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/1992 - "The present study was undertaken to examine the effects of excess factor D build-up in the body of end-stage renal disease (ESRD) patients upon the activation of the alternative pathway and the terminal pathway in the fluid phase" 01/01/1992 - "The results showed that once the serum factor D level reached a concentration corresponding to 15 micrograms/ml in the serum of the ESRD patient, the C3a-des-Arg and C5a-des-Arg levels had climbed to about 1.7-fold the concentration in normal serum" 01/01/1992 - "First, to clarify the effect of excess factor D on the alternative pathway, purified factor D from an ESRD patient was added to normal serum and the changes in concentrations of C3a-des-Arg and C5a-des-Arg were investigated" 10/01/1989 - "A number of in vitro assays were used to analyze AP activation in normal human serum (NHS), in normal serum supplemented with purified factor D to 10-fold its normal concentration (10 x D), and in sera of patients with ESRD" 01/01/1991 - "First, we estimated the concentration of factor D, ICSA and the hemolytic activity via the classical complement pathway (CH50) in the sera of 16 healthy individuals and 36 patients on hemodialysis for end-stage renal failure" Order ALL the reference details at left...
2.	Obesity 08/01/1999 - "CONCLUSION: The present data suggest involvement of the ASP/adipsin pathway in the pathogenesis of obesity." 11/18/1994 - "Independent regulation of adipose tissue-specificity and obesity response of the adipsin promoter in transgenic mice." 08/01/1993 - "It has been suggested that this reduction in adipsin is causative to obesity development" 08/01/1993 - "Adipsin is a molecular marker of obesity in rodents" 06/01/1992 - "What is the role of adipsin in obesity?" Order ALL the reference details at left...
3.	Infection 12/01/1989 - "This study describes the first complete deficiency of factor D, and demonstrates its possible relation to recurrent Neisseria infections." 03/01/2003 - "AdL466A infection also blocked the upregulation of the adipocyte marker genes aP2 and adipsin" 12/04/2001 - "Kinetics of opsonization of Streptococcus pneumoniae by C3 fragments was much slower in factor D-deficient serum, suggesting a significant contribution of the alternative pathway to antibacterial host defense early after infection." 07/01/2001 - "Increased susceptibility for infections in individuals with a partial factor D deficiency is unlikely." 12/01/1989 - "A young man suffering from recurrent Neisseria infections was shown to lack detectable serum complement factor D hemolytic activity" Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 02/01/2004 - "Among the most significant findings, an adipsin polymorphism was associated with increases in body weight, total fat mass and subcutaneous fat in response to overfeeding" 09/01/2003 - "Overfeeding induced greater increases in body weight, fat mass, abdominal total and subcutaneous fat (P<0.05) in 6.1 kb noncarriers (n=10) than in 6.1 kb carriers (n=14) of the adipsin Hinc II polymorphism" 12/04/2001 - "The mutant mice have no apparent abnormality in development and their body weights are similar to those of factor D-sufficient littermates" 06/01/1997 - "Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity." Order ALL the reference details at left...
5.	Acute Kidney Failure (Acute Renal Failure) 01/01/1996 - "The aim of our study was to measure the time course of factor D adsorption and its blood concentration during CVVH in critically ill patients with acute renal failure" 11/01/1995 - "Because of their effect on the immune response, especially in patients with chronic or acute renal failure, factor D (FD) and the immunosuppressive complement fragment Ba are substances which may be important for the immunological status" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Complement Factor D (Factor D)
3.	Sodium Glutamate (Accent)
4.	Messenger RNA (mRNA)
5.	Caffeine (No Doz)
6.	Ephedrine
7.	Antigen-Antibody Complex (Immune Complex)
8.	A-Form DNA (A-DNA)
9.	Interleukin-6 (Interleukin 6)
10.	Serine Endopeptidases (Serine Protease)

Related Therapies and Procedures

1.	Caloric Restriction
2.	Renal Dialysis (Hemodialysis)
3.	Lipectomy (Liposuction)
4.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
5.	Peritoneal Dialysis

Best Treatments:
Research Summary Report
on Chronic Kidney Failure

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 810 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface